delphi_genetics

Catalent acquires Delphi Genetics for $55M

Catalent Pharma takes over Delphi Genetics. The Gosselies BioPark will be its European Center of Excellence in Gene and Cell Therapy. Delphi Genetics is one of ULB‘s oldest spin-offs, created twenty years ago. The company, which employs around 40 people, is a pharmaceutical subcontracting company (CDMO) specializing in cell and gene therapies. Its mission is not to develop treatments,[…]

DSC_1875-copie-scaled2

Novadip receives 9.4 M€ of non-dilutive funding

The Walloon Region Government to support the development of treatments at Novadip with 9.4M€ of non-dilutive funding Novadip Biosciences, a clinical-stage company developing treatments to regenerate damaged tissues in patients with significant unmet medical needs, has announced that the US Food and Drug Administration (FDA) has granted the designation of Rare Pediatric Disease and Orphan[…]

1600335902672

OUAT! raises 500k€ with the Innovation Fund

  OUAT! recently raised 500k€ with the Innovation Fund. The capital infusion will support the further development of HakoBio and the roll out of the software to new clients. OUAT! aims to facilitate the digital transformation of the life sciences industry. In increasingly intelligent and connected factories, OUAT! enables the men and women of the biopharmaceutical industry to achieve[…]

1608194538472-square-2

Univercells raises €70 million in Series C Financing

Univercells Holding recently raises €70 million with two rounds of capital increase with new investors. The capital infusion will support the development of GMP facilities and the capacity to foster distributed manufacturing and supply of biologics. Univercells recently completed their Series C second close, bringing the total raised to €70 million. The financing, which was over-subscribed,[…]

George Soros

Univercells, beneficiary of financial support from major investors

Many large investors have already set their sights on the Walloon company Univercells. Among them stands out the American billionaire George Soros; famous financier and philanthropist at the age of 90, Adjuvant Capital; a fund linked to the Bill Gates galaxy, the federal government through SFPI, and the Walloon government through SRIW. Bill Gates, as[…]

tibia_actu2_def copy

World first: a child’s tibia healed thanks to a 3D bone graft from Novadip technology

  This is a world first in the field of orthopaedic surgery: surgeons at Cliniques universitaires de Saint-Luc repaired the tibia bone of a 5-year-old child using a bone graft implant, a technology developed by the UCLouvain spin-off Novadip Biosciences. The child had congenital nonunion of the tibia, a rare and disabling disease. He was[…]

univercells_bill_gates

Bill Gates invests in Univercells again

    Univercells has just completed a new funding round of around 50 million €. Among its investors, a fund linked to the Bill & Melinda Gates Foundation, which has already helped the Walloon biotech on several occasions. The list of investors includes Adjuvant Global Health Technology Fund, a fund originally linked to the Bill & Melinda Gates[…]

novadip_3M3_platform

Novadip unveiled its 3M³ Platform at BIO Digital 2020

Unique 3M3 tissue regeneration technology platform generates multiple product candidates: autologous, off-the-shelf and miRNA/exosome Novadip Biosciences, a clinical-stage biopharmaceutical company leveraging its unique tissue regeneration technology platform to generate multiple product candidates, announces that it will unveil details of its 3M3 miRNA delivery platform in a recorded presentation at the BIO Digital conference, which is took place[…]

bonehealing

Novadip progresses in bone healing treatment

Great news for Novadip published in L’Echo and Trends Tendances. Novadip Biosciences – biotech active in cell therapy – has recorded very encouraging results for its product candidate intended to repair large non-healing fractures of the lower limbs in adults. The UCLouvain spin-off has developed a revolutionary process for reconstructing bones from stem cells drawn from the patient’s fat.[…]

pdcline_bfmbusiness

PDC*line Pharma on BMF Business

Eric Halioua, President & CEO of PDC*line Pharma, was invited on BMF Business to speak about the new class of immunotherapies active against cancer which his team is developing. Watch the replay here: Contact us to get more information: Source: https://bfmbusiness.bfmtv.com/mediaplayer/video/eric-halioua-pdcline-pharma-pdcline-pharma-developpe-une-nouvelle-classe-d-immunotherapies-actives-contre-les-cancers-0205-1244108.html  

favicon_20200415_Press-Release-COVID19-Vaccine

Univercells announces fast-track development of a COVID-19 vaccine with ReiThera and Leukocare

ReiThera, LEUKOCARE and Univercells announce pan-European consortium for the fast-track development of a single-dose adenovirus-based COVID-19 vaccine. Italian ReiThera Srl. (Rome), German LEUKOCARE AG (Munich), and Belgian Univercells S.A. (Brussels), today announced a strategic collaboration for the development and large-scale manufacturing of a novel adenoviral vector-based vaccine against COVID-19. The vaccine candidate is expected to enter[…]

univercells_coronavirus_bultot

Univercells in the race for the coronavirus vaccine

With the novel coronavirus continuing its global spread, drugmakers are pouring massive resources into developing targeted therapies and vaccines. Now, a new CDMO from Belgium’s Univercells is hoping its expertise can help drugmakers scale up their manufacturing for a successful shot. Univercells has launched Exothera, a viral vector CDMO targeting cell and gene therapy and vaccine developers, in a refurbished 15,000-square-meter[…]

pdcLine-Pharma-dendritic-cell-cancer-vaccine

PDC*line Pharma announces the administration of a first patient with its therapeutic cancer vaccine candidate targeting non-small cell lung cancer

Liège, Belgium and Grenoble, France, March 3, 2020 – PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, announces today that the first patient was dosed with its innovative medicinal product candidate PDC*lung01 in a phase I/II trial in non-small cell lung cancer (NSCLC). This patient is under[…]

univercells_press_release

Univercells secures up to €50M investment from KKR platform

BRUSSELS, BELGIUM – FEBRUARY 18,2020 — Univercells, an innovative bioprocessing provider focused on increasing the availability of affordable biologics to address global health challenges, has announced up to EUR 50M financing from Gamma Biosciences, a new investment platform supported by leading global investment firm KKR, that is focused on next-generation bioprocessing technologies for the production of advanced[…]

MaSTherCell_250x250

MaSTherCell is acquired by Catalent for $315 Million

GOSSELIES, BELGIUM – February 3, 2020 — MaSTherCell S.A., a subsidiary of MaSTherCell Global, Inc., a subsidiary of Orgenesis Inc. (NASDQ: ORGS) a technology-focused cell and gene therapy contract development and manufacturing partner to leading cell therapy innovators, today announced an agreement to acquire MaSTherCell Global that has been reached between the owners of MaSTherCell Global and Catalent Pharma[…]

pdc_biotech_finances

PDC*line Pharma’s recent fund raising is described in the latest issue of Biotech Finances

Check the latest issue of Biotech Finances to read an interview of PDC*line Pharma’s President & CEO Eric Halioua describing the recent fund raising completed and the perspectives of the company.   Read the full article: https://www.biotech-finances.com/126504-2/ Contact us to get more information:

blqDNtyA

Our client PDC*line Pharma raises $22.2M in series B financing round

Liège, Belgium and Grenoble, France, January 22, 2020 – PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, announces today the completion of its Series B round of financing. The company has raised a total of €20 million ($22.2M). Two and a half years after its last round of[…]

BioWin_gdv

We gave a lecture about clinical trials funding at “Anchoring Clinical Research in Belgium”

We took part in the event “Anchoring Clinical Research in Belgium” jointly organized by BioWin and flanders.bio in Brussels where we had an interesting debate on funding opportunities for biomedical research and clinical trials development in a sector where Belgium is leading globally. Thank you to Bone Therapeutics, icometrix and Ayming Belgium for sharing the stage.              […]